Navigation Links
DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin

HELSINGBORG, Sweden, April 14, 2008 / b3c newswire /   -  DuoCort AB announced today that it will host a satellite symposium – Optimized Care for Adrenal Insufficiency – at the 10th European Congress of Endocrinology (ECE 2008) at the Internationale Congress Centrum in Berlin.  The symposium will be held on Tuesday May 6, 1pm–2.30pm, in Hall 7.  All delegates attending ECE 2008 are invited to the symposium.

Prof emer Michael Besser will chair the symposium, which also features a number of other authorities in the field:  Dr John Newell-Price, Prof Brian R Walker, and Dr Gudmundur Johannsson, Chief Medical Officer of DuoCort.  The symposium will cover key aspects and recent developments in therapy for adrenal insufficiency, including choice of glucocorticoid and dosing, outcomes from current therapy, and ways to improve glucocorticoid replacement therapy. 

DuoCort is developing a once-daily dual-release hydrocortisone tablet for adrenal insufficiency.

In December 2007, DuoCort completed the targeted enrolment in the pivotal phase II-III clinical trial evaluating 5 mg and 20 mg DuoCort™ dual-release hydrocortisone tablets for the treatment of adrenal insufficiency – the inability of the body to produce sufficient amounts of the essential hormone cortisol. The first data from the study is expected to be available in Q3 2008.

“Current research confirms that conventional therapy is suboptimal and is not serving these patients as well as it should.  There is scope for improvement in the delivery of cortisol replacement and we are convinced DuoCort will deliver better long-term outcomes.  This trial is a major step toward offering a better treatment option for patients with adrenal insufficiency”, commented Dr Johannsson.

For more information about DuoCort and its drug development programs, contact Greg Batcheller, CEO, tel. +46 46 288 5008.

Notes to the editor

About adrenal insufficiency
Recent research on adrenal insufficiency patients taking currently available glucocorticoid replacement therapy demonstrates reduced bone density, unfavourable cardiovascular risk profiles and compromised quality of life and well-being.  Recent data also suggest an almost 3-fold increased mortality. Improvement in the replacement regimen and replacement strategy is therefore essential. Chronic adrenal insufficiency is a rare disease that affects over 125,000 patients in the European Union and over 100,000 in North America.
About DuoCort™ dual-release hydrocortisone DuoCort™ dual-release 5 mg and 20 mg hydrocortisone tablets for patients with chronic adrenal insufficiency were granted an Orphan Medicinal Product Designation in the European Union in May 2006.  DuoCort’s objective is to improve today’s glucocorticoid replacement therapy with a tablet that delivers a more physiological profile of hydrocortisone, better mimicking the body’s natural cortisol release by combining rapid release and extended release characteristics.  DuoCort™ is a once-daily tablet that is more convenient than current therapy.

About DuoCort AB
DuoCort AB is a drug development company focused on improving glucocorticoid therapy in areas of significant unmet medical need. The company is based in Helsingborg, Sweden.

b3c newswire

Related biology technology :

1. Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium
2. Pharsight Hosts Fourth Annual PKS User Group Meeting
3. Germany Hosts World Leading Medical Industry Fair
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
6. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
7. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
8. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
11. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
Post Your Comments:
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
Breaking Biology News(10 mins):